IDENTIFICATION OF NEW MOLECULAR BIOMARKERS - PROTEOMICS
The pathogenesis of the tumor is extremely complex and can not be fully explained by the existing methodological approaches. Proteomics is an interdisciplinary science that deals with the study of proteins, carriers of the biological functions of the organism. It encompasses a series of methods for protein analysis and provides exceptional possibilities for understanding the molecular basis of the disease, the possibilities of early diagnosis, and the production of new drugs. Proteomic analyzes of the malignancy altered tissue have revealed proteins involved in the progression of the disease, and thus contributed to the discovery of potential drug treatment methods. Proteomics provides a better understanding of the molecular basis of these diseases, plays a role in the diagnosis of the same, and it is expected to make a significant contribution to the development of new more effective drugs and the development of personalized therapy.
Ratkaj I, Kraljević Pavelić S. Istraživanje patogeneze raka dojke uz pomoć metoda proteomike. Medicina Fluminensis. 2009;45(3):270-5.
Li W, Li C, Zhou T, Liu X, Liu X, Li X et al. Role of exosomal proteins in cancer diagnosis. Mol Cancer. 2017; 16(1):145.
Gonzalez de Castro D, Clarke PA, Al‐Lazikani B, Workman P. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther. 2013;93(3):252-9.
Kraljević Pavelić S, Pavelić K. Novo doba molekularne medicine: dometi proteomike. Medicina Fluminensis. 2009;45(3):208-10.
Damjanović S, Pe P. Genski markeri karcinoma glave i vrata – savremena saznanja i perspektive. Jugoslov Med Biohem. 2003; 22(4):273-82.
Kraljevic Pavelic S, Saban N. Evolving ‘-omics’ technologies in the drug development process. Expert Opin Drug Discov. 2007; 2(4):431-6.
Kraljević Pavelić S, Šaban, N. Uloga proteomike u otkrivanju novih protutumorskih lijekova. Medicina Fluminensis. 2009;45(3): 211-17 .
Verrills NM. Clinical proteomics: present and future prospects. Clin Biochem Rev. 2006; 27(2): 99-116.
Fontana S, De Leo G, Sedic M, Pavelic SK, Alessandro R. Proteomics in antitumor research.Drug Discovery Today: Technologies. 2007; 3(4): 441-9.
Petricoin E F, Ardekani A M, Hitt B, Levine PJ, Fusaro VA, Steinberg SM et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002; 359(9306): 572-7.
Mukhina S, Mertani HC, Guo K, Lee KO, Gluckman PD, Lobie PE.. Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone. Proc Natl Acad Sci U S A. 2004; 101(42):15166-71.
Pastwa E, Somiari S. B, Czyz M, Somiari RI. Proteomics in human cancer research. Proteomics Clin Appl. 2007; 1(1): 4-17.
Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497(7447): 67-73.
Feng XP, Yi H, Li MY, Li XH, Yi B, Zhang PF. Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics. Cancer Res. 2010; 70(9): 3450-62.
Lee J M., Kohn E. C. Proteomics as a guiding tool for more effective personalized therapy. Ann Oncol. 2010; 21(suppl 7): 205-10.
- There are currently no refbacks.
Copyright (c) 2018 Sladjana Vujacic
This work is licensed under a Creative Commons Attribution 4.0 International License.